Header Image



Two different CAR-T assets in clinical stage through Partnerships:

  • CD19 CAR-T therapy for Non Hodgkin’s Lymphoma (NHL)
  • Bi-specific CAR targeting CD19 and CD22 in relapsed/refractory

                               Diffuse Large B Cell Lymphoma (DLBCL)

MTB–001CD19Non Hodgkin’s Lymphoma (NHL)   
MTB-002CD19 and CD22relapsed/refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL):   
MTB-003MultipleMultiple myeloma   


CD19, 22

Hematologic indications   
MTB-005UndisclosedSolid tumors   

MTB-001: IND approved; US trials through our partner; global trials through MedTherapy
MTB-002: Similar constructs under Phase-I. MedTherapy Phase I starting in 2023
MTB-003, MTB-004, MTB-005: Co-development with our partners.



Next-generation CAR-T cell therapies

  • Ability to rapidly and cost-effectively manufacture and scale up CD19 CAR-T cells
  • Development of novel CD19 CAR technology that demonstrates similar or improved efficacy to other clinically used CD19 CAR products
  • Our CAR-T cells demonstrate similar or improved in vitro and in vivo efficacy to commercial CAR-T products against human lymphoma cells
  • Novel CAR design based on unique hinge and transmembrane domains with high level of CAR expression and activity (IP filed by our collaborating partner)
  • Our CAR-T cells maintain immature/memory phenotype and demonstrate enhanced circulating CAR-T cells
  • Delivery Time = 1 week; compared to 4-6 weeks for other commercial manufacturing


Next-generation technologies for CAR-T cell therapies

Innovative Manufacturing Technology:

Manufacturing CAR-T cell gene therapies is very complex. And time consuming – almost 4-6 weeks for a patient.

This leads to both- delays in manufacturing, and, exorbitant costs. MedTherapy has developed innovative technologies to speed up the process. Our technology allows to manufacture the therapy in a few days – instead of weeks!

Virus vector technology:

Our in-house global scale manufacturing facilities are capable for industry scale manufacturing for ourselves and our partners and collaborators.

Current, classical: quadruple transfection of adherent 293T cells in cell factories

Novel: quadruple transfection of 293T cells in suspension in bioreactors

Unique: lentiviral vectors produced from stable cell line (no plasmid DNA needed)

Disruptive: production of injectable targeted lentiviral vectors